availability status of several specialties

Disruption of sales, tensions/interruptions in supply and resumption of availability.Peterspiro / iStock / Getty Images Plus / via Getty Images

EBetween 12 and 23 April 2024, the National Agency for the Safety of Medicines and Health Products (ANSM) reported new failures or updated the availability of several specialties marketed in France. [1]distributed exclusively to the hospital.

METHOTREXATE TEVA for injection: quota for 2 links

METHOTREXATE TEVA 10% (5 g/50 ml), METHOTREXATE TEVA 10% (1 g/10 ml), METHOTREXATE TEVA 2.5% (50 mg/2 ml) and METHOTREXATE TEVA 2.5% (500 mg/20 ml ) injection solution (methotrexate)

Availability status according to ANSM

NOVANTRON 10 mg/5 ml: sales discontinued.

NOVANTRON 10 mg/5 ml concentrate for solution for infusion (mitoxantrone)

Availability status according to ANSM

Additional information from the laboratory

Viatris Laboratory Newsletter for Hospital Pharmacists (January 2024): “Given the hospital-only nature of this drug, boxes and vials will not be labeled with a new expiration date, but each unit of Lot P00042H will be accompanied by this letter.”

PLEGISOL: supply voltage again

PLEGISOL cardioplegic solution for injection

Availability status according to ANSM

TILDIEM injection: out of stock from April 16, 2024

TILDIEM 25 mg powder and solution for intravenous injection (diltiazem)

Situation: separation.

Expected delivery date: end of May 2024

Additional information from the laboratory

Sanofi Winthrop Industrie laboratory fact sheet dated April 22, 2024 for the attention of healthcare professionals, suggesting alternatives for indications (Wed Excerpt from the letter below).

Excerpt from Sanofi Winthrop Industrie laboratory letter dated April 22, 2024 to healthcare professionals